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ABSTRACT

Proliferative vitreoretinopathy (PVR) is a disease of the retina in the human eye. Retinal
pigment epithelium cells (RPE) undergo an epithelial to mesenchymal transition in
response to retinal trauma. This transition gives the cells mobility and allows them to
potentially infiltrate the vitreous chamber and deposit on either side of the retina. Once cell
deposition has occurred, along with several other transformed cells derived from cell types
such as Müller glia, these migratory cells can form a membrane contiguous with the retinal
extracellular matrix and, upon contraction, cause wrinkling of the retina. If left untreated
PVR can lead to traction retinal detachment and blindness.
There are limitations to the methods currently being used to treat this disease. The most
common treatment option for PVR is surgery, which has a limited success rate.
Pharmacological agents, such as the protein kinase inhibitor dasatinib, are also being
investigated for their efficacy in treating this condition. Dasatinib has been shown to
prevent PVR and associated cellular functions in porcine animal models in a dosedependent manner. One of the limitations of using dasatinib, however, is the need for
recurring drug injections to keep a therapeutic level in the eye and prevent retinal
contracture.
Targeted ocular drug delivery, through the use of polymeric nanoparticles, offers a
promising method to deliver dasatinib to the eye without the need for frequent daily
injections. In this project, spray drying, a technique that produces drug-encapsulated
polymer shells from a liquid dispersion, was used to encapsulate dasatinib in PLGA
iv

particles. Particle size was optimized to produce particles under 1 µm in diameter through
the use of a Taguchi statistical design approach. Particles were manufactured on a Büchi
B-90 nanospray spray dryer. PLGA particle optimization was completed before the
production of PLGA dasatinib particles. After PLGA particle optimization, PLGAdasatinib particles were produced (n = 3) and their size analyzed using scanning electron
microscopy. The release kinetics of dasatinib from the PLGA particles was analyzed using
UV-Visible spectroscopy from this the drug release kinetics and mechanism was
determined.
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NOMENCLATURE

PLGA:

poly-lactic-co-glycolic acid

PBS:

phosphate buffered saline

PVR:

proliferative vitreoretinopathy

RPE:

retinal pigment epithelium

EMT:

epithelial mesenchymal transition

ECM:

extracellular matrix

PDGF:

platelet derived growth factor

PDGFR:

platelet derived growth factor receptor

DCM:

dichloromethane

(w/v %):

percent weight by volume

µm:

micrometer

µM:

micromolar

C:

degrees Celsius

L/min:

liters per minute

BSA:

bovine serum albumin

PLGA-D:

PLGA dasatinib particles

PPV:

pars plana vitrectomy

SEM:

scanning electron microscopy

EHT:

electron high tension
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I. INTRODUCTION
A. Anatomy of the Eye:

To understand the disease process of proliferative vitreoretinopathy it is useful to first
understand the basic anatomy of the human eye. The shape of the human eye is an oblate
spheroid that has three primary layers: the fibrous coat, vascular coat, and nervous coat.1
A basic schematic of the anatomy of the eye can be seen in Figure 1. The outermost layer
of the eye is the cornea which acts as a transparent meniscus lens that aids in focusing light
on the retina.2,3 The cornea is the anterior 1/6 of the fibrous coat which comes in contact
with the environment. The remaining 5/6 of the fibrous coat of the eye is made up of the
sclera, which is commonly referred to as the whites of the eye. The sclera of the eye helps
maintain ocular shape and protect the eye from trauma.4 The meeting point between the
cornea and the sclera is known as the limbus.

FIGURE 1. Anatomy of the human eye5

1

The vascular coat of the eye serves to nourish the eye and is made up of the iris,
ciliary body, and choroid. The iris acts as a control point for the amount of light reaching
the retina through dilation and constriction of the pupil.2 The lens of the eye is posterior to
the iris. The space between the iris and the lens of the eye is known as the posterior
chamber. The ciliary body of the eye controls the lens as well as aqueous humor
production.6 The choroid is the main vascular tissue of the eye and provides nourishment
to the organ.
The nervous coat of the eye is composed of the retina, which is the part of the eye
that is responsible for vision. The retina is the innermost layer of the eye and contains
specialized cells called rods and cones that help the eye process light through the
conversion of the electromagnetic waves into neural impulses processed by the brain,
Figure 2.4

FIGURE 2. Anatomy of the human retina
2

The retina lines the posterior portion of the eye and is around 0.5 mm in thickness.7
It communicates with the brain through the optic nerve which inserts into the retina
producing the optic disc, the blind spot in human vision. The human retina has three layers
of nerve cells and two layers of neuronal synapses, Figure 3.

FIGURE 3. Anatomy of the human retina with neuronal layers8
The cells that line the most posterior portion of the retina are the retina pigmented
epithelium cells (RPE), which are a main contributor in the disease of proliferative
vitreoretinopathy (PVR). The next layer of cells in the retina which contain the rods and
cones which project into the RPE.8 Following the layer of rod and cone projections into the
RPE is the outer nuclear layer which contains the cell bodies of the rods and cones. After
this layer is the inner nuclear layer, followed by the inner plexiform layer, the ganglionic
layer,a layer of optic nerve fibers, and the inner limiting membrane.
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Light must travel through the layers of the retina before it is able to activate the rod
and cone cells of the eye.9 After activating the cells through the absorption of photons the
light is converted into a biochemical message that is further modified into an electrical
signal which is transduced to the nervous cells of the retina and then relayed to the brain.
The retinal pigment epithelium (RPE) lining the posterior portion of the eye is integral in
the development of PVR.
The RPE is a monolayer of cells that is part of the blood retinal barrier.9 It plays a
wide variety of roles in maintaining the retinal environment for the rods and cones which
it intimately interacts with. The basolateral membrane of the RPE faces Bruch’s membrane.
Microvilli on the apical surface of the RPE complex with the outer portions of the photo
receptors and work to maintain the retinal microenvironment necessary for vision.
One of the RPE’s functions which is necessary for sight in the human eye is the
absorption of light which is focused on the retina by the lens.9 The RPE forms a dark
pigmented wall which aids in the absorption of scattered light. Another function of the RPE
is ion transport between the photoreceptors of the eyes and the choriocapillaries. The large
amount of metabolic turn over in the retina and intraocular pressure from the vitreous body
to the retina produces water which must be removed from the retinal space. Water from the
inner retina is transported by the Müller cells and water from the subretinal space is
removed by the RPE. The RPE transports water and ions from the subretinal space into the
choriocapillaries. In addition to moving water and ions the RPE also removes metabolic
waste products produced by the photoreceptors.
Along with transporting water and electrolytes from the subretinal space to the
choroid, the RPE also transports glucose and other nutrients from the blood to the
4

photoreceptors of the eye.9 The RPE maintains the excitability of the rods and cones by
transporting all-trans-retinal and isomerizing it to all-cis-retinal before returning it to the
photoreceptors. Photoreceptor excitability is also maintained through the phagocytosis of
worn out photoreceptors by the RPE. The RPE also secrets growth factors and
immunosuppressive factors into the eye. The RPE plays many vital functions in the eye
and a disruption in any one of the functions can result in damage to the retina and loss of
vision.
B. Proliferative Vitreoretinopathy
The Retina Society Terminology defined proliferative vitreoretinopathy as the
growth of cellular membranes on the anterior and posterior surfaces of the detached retina
and the posterior hyaloids.10,11 PVR is marked by the migration of cells onto the retinal
surfaces in response to chemical signals associated with wound healing. The disease
process can be divided into several stages: cell migration and proliferation, extracellular
collagen production and membrane development, and contracture of membrane that causes
folding and/or detachment of the retina.12 This contracture of the retina proceeds tractional
retinal detachment and is the most common cause for retinal detachment following surgical
interventions.13 In 1981 the Retina Society Terminology classified the physiological
conditions previously known as massive vitreous retraction (MVR), massive preretinal
retraction (MPR), massive periretinal proliferation (MPP) and massive preretinal
fibroplasia (MPF) under the name of PVR and classified the disease into grades of
severity.14
Retinal detachment from the underlying retinal pigment epithelium (RPE) can be
caused by traction forces on the retina or impairment of RPE pump function.15,16 Such
5

detachment causes tissue trauma and induces inflammatory and wound healing responses
of the body that can lead to PVR.11,17,18 Several cell types have been implicated to play
roles in PVR including: retinal pigment epithelium, mononuclear leukocytes, microglia,
and Müller glia. In the first few days following retinal injury, proliferation of Müller cells
occurs.16 In the normal retina, Müller glial cells cover the entire retina, providing it with
structural and metabolic support. In response to injury, reactive Müller cell gliosis occurs
and is thought to be a protective mechanism to prevent further tissue damage and promote
retinal repair. This response by the Müller cells is associated with the release of
proinflammitory cytokines and growth factors, which in the adult mammalian retina can
lead to further degeneration and damage.
The RPE is a single layer of cells that lines the Bruch’s membrane. RPE cells gain
access to the vitreous cavity through retinal holes and/or tears that often accompany retinal
detachment.19 Loss of cell-cell adhesion triggers cells to undergo an epithelialmesenchymal transition (EMT) rendering them similar to fibroblasts in morphology. This
transition changes epithelial cells phenotypes to display one associated with mesenchymal
cells including increased mobility, resistance to apoptosis, increased ECM production, and
greater invasive properties.20,21 These cells are further stimulated to proliferate by a
combination of growth factors/cytokines from the vitreous and inflammation that includes
transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), and
thrombin.22
Both activated Müller cells and RPE cells that have undergone EMT can further be
induced to become myofibroblasts, which are positive for strongly contractile α-smooth
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muscle actin (α-SMA).23 Myofibroblasts are considered to play a critical role in various
fibrotic diseases including PVR.
Various growth factor receptors such as platelet-derived growth factor receptors
(PDGFR) have been found in the epiretinal membranes formed in PVR.24,25 Kazlauskas
and colleagues have conducted a series of studies demonstrating the importance of
PDGFR-α in PVR associated cellular functions in vitro and in a rabbit model of PVR in
vivo. Such receptors can be targeted molecularly through the use of pharmaceutical agents,
including the drug dasatinib.26 Targeting these cellular growth factors may be used to
prevent or slow the formation of PVR in the eye.

C. Current Treatments and Limitations
Surgery is currently the preferred method of treatment for PVR.12 The aim of retinal
surgery is to alleviate retinal traction and repair the break in the retina to reinstate as much
healthy retinal anatomy as possible. The most common procedure performed for PVR is
pars plana vitreoctomy with membrane peeling.15 Light to moderate cases of PVR are most
easily treated with surgery, while severe PVR requires complicated surgery, as examined
by Mendes, e. al.27 The study evaluated retinectomy to treat severe proliferative
vitreoretinopathy. Thirty-eight patients with PVR grade C3, which is considered severe
PVR, underwent retinectomy which increased the rates of final retinal reattachment.
Various drugs and pharmacological agents including anti-inflammatory drugs,
antiproliferative agents, and growth factor pathway inhibitors.

7

Anti-inflammatory drugs are commonly used to try to prevent PVR.12 Proteometric
analysis of the vitreous samples of patients with PVR has shown up-regulation of
inflammatory markers. Triamcinolone (a glucocorticoid) was first used by Jones, et al.
along with pars plana vitrectomy (PPV) and silicone oil with conflicting results. Prednisone
is another anti-inflammatory commonly used to treat this physiological condition, but
requires further research to determine its efficacy. Other pharmacological agents that have
been used to treat the disease among which is 5-fluorouracil an antiproliferative agent.
Antiproliferative

agents

have

been

used

to

treat

PVR

with

mixed

results.13Antiproliferative agents are used to inhibit the cell cycle and cellular proliferation
of RPE cells following the break in the retina. The most commonly used antiproliferative
agent is 5-fluorouracil (5-FU). It inhibits thymidine formation, thereby preventing DNA
synthesis in actively proliferating cells. When used in clinical trials 5-FU was shown to
reduce the rate of postoperative PVR following rhegmatogenous retinal detachment
surgery (RRD).29
Cellular growth pathway inhibitors, such as those that interfere with kinase
enzymes, are another method being examined to control PVR.13,30 Kinases participate in
transducing extracellular signaling into gene expression changes such as EMT. Inhibiting
signaling pathways involved in PVR has been shown to prevent EMT, thus preventing
formation of the epiretinal membrane.20 Ranibizumab, a vascular endothelial growth factor
inhibitor, has been shown to prevent PVR in rabbit models.15 Kinase inhibitors work later
in the cell signaling pathway and may halt the PVR process.
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D. Dasatinib and Proliferative Vitreoretinopathy:
Dasatinib is a dual tyrosine kinase inhibitor developed to inhibit SRC family
kinases and Abl kinase.31 Dasatinib is currently Food and Drug Administration (FDA)
approved for the treatment of chronic myeloid leukemia under the trade name of
Sprycel.32,33 Umazume, et al. tested dasatinib’s ability to prevent the PVR-associated
cellular changes on cultured RPE cells from swine.34 A porcine in vivo model for PVR was
subsequently used to evaluate the level of retinal traction in the eye caused by PVR.
Dasatinib was shown to prevent RPE growth in a dose-dependent manner with a dose of
0.1 µM inhibiting 80% of vitreous fluid-stimulated collagen gel contraction. A total of
eleven porcine eyes were injected with dasatinib to look at the formation of the retinal
membrane and retinal traction. Due to the low residence time of dasatinib in the vitreous
humor, injections were made into the eyes on day 0, 3, 7, and 10. Only one of the eleven
eyes injected with dasatinib presented with retinal detachment while all eleven control eyes
had retinal detachment. The use of multiple injections of dasatinib to prevent the formation
of PVR makes the drug an ideal candidate for a drug delivery system which would remove
or lower the need for frequent injections.

9

E. Ocular Drug Delivery

FIGURE 4. Routes of ocular drug delivery35
Drugs can be targeted to the eye through several different routes: intravitreal,
subconjunctival, systemic application, and topical application among others.36 PVR is a
disease that affects the retina, which is therefore the primary target area for drugs intended
to prevent PVR pathology. The retina has several barriers that make drug delivery
challenging.37 The blood retinal barrier (BRB) is the posterior barrier to drug delivery and
the blood aqueous barrier (BAB) is the anterior barrier for drug delivery to the retina.38 The
BRB restricts the permeability and diffusion of substances between the retina and the
blood. It relies primarily on active transport to move substances across the barrier making
passive drug diffusion difficult.30 The BAB is composed of the ciliary epithelium and the
capillaries of the iris. Like the BRB its function is to tightly regulate substances that can
get into the eye which makes drug delivery difficult.
Topical drug delivery is appealing for drug delivery to the anterior portion of the
eye (aqueous humor, iris-ciliary body, and lens), however, it has low bioavailability when
10

diffusing through the layers of the eye to reach the retina.37 Less than 5% of the delivered
topical dose has been shown to reach the deeper layers of ocular tissue.39 Additionally,
enzymatic degradation of the drug occurs before it can reach the posterior segment of the
eye.
Systemic drug delivery typically has low ocular bioavailability of the drug, with
between 1-2% reaching the posterior portion of the eye. The lack of drug reaching the
posterior segment of the eye requires frequent injections to sustain necessary therapeutic
levels. Systemic drug delivery also allows nonspecific absorption of the drug by other
tissues.
Drugs delivered into the eye cavity through periocular injection typically do not
reach the retina because it lies behind the lens which acts as a barrier.36 The sclera of the
eye provides a large surface area, though it has extensive blood vessel networks through
which drugs can diffuse and be removed through before reaching the retina.
Intravitreal injection is the most common method of drug injection to reach the
posterior segment of the eye including the retina.39 Intravitreal injections have several
shortcomings, however, such as the need for repeated injections.37 One of the ways
researchers have tried to combat this problem is through increasing the drug residence time
in the vitreous humor using a drug delivery vehicle.

F. Controlled Drug Release
Controlled drug release systems are an advancement in drug delivery technology
that enables targeting of specific parts of the body while limiting systemic drug exposure,
11

increasing the ability of drugs to cross physiological barriers, prolonging drug release in
situ and helping prevent premature release of the drug.36 The increased efficiency in
delivering drugs to their target can be used to decrease the overall drug dosage and the
amount of the drug needed for therapeutic levels.
Nanoparticles/sub-micron particles, ranging in size from 10 – 1000 nm, have been
researched extensively for use as drug delivery systems. For ophthalmologic drug delivery,
particles are typically composed of either lipids, proteins, or polymers.39 Nanoparticles
have been used for a long-term drug delivery solution to the posterior components of the
eye. Once injected into the vitreous humor of the eye nanoparticles have been shown to
accumulate on the RPE. The various drug release profiles of particles can be divided into
slow sustained release and particles that experience a burst release followed by sustained
release.40 The zero-order model of drug release kinetics is for nanoparticles which do not
undergo disintegration and release the drug at a slow steady rate until no drug remains. The
first order model of drug release kinetics can also be used to describe particles which did
not experience an initial burst release and is typically seen in water soluble drugs in a
porous matrix. The Higuchi model of drug release was first elucidated in 1961 and was
used to describe drug release kinetics from planar systems. Takeru Higuchi developed the
model based on drug release from thin ointment films which is modelled as drug release
into a perfect sink.41 The Higuchi model of drug release is best used to predict drug release
from a permeable matrix when the amount of drug released is greater than the solubility
limit.42 The model, however, has since found utility in characterizing drug release in
particles as well. The Hixon-Crowell model of drug release is used when the drug release
is parallel to the surface on which dissolution will take place. Its application primarily
12

exists in dissolvable tablets for drug delivery. The Korsmeyer-Peppas model of drug
delivery was developed for drug release from a polymeric system. In addition to the above
drug release kinetics, there are several “special application” models which have not been
covered.
Particles employed for ocular drug release have shown a variety of drug
release kinetics models. For example, chitosan sodium alginate nanoparticles used for
ocular drug delivery were found to have an initial burst release followed by a longer
sustained drug delivery period.43 Another set of chitosan nanoparticles loaded with
cyclosporine A for the treatment of extraocular disease were also found to have an initial
burst release followed by sustained drug release.44 Poly (lactic-co-glycolic) acid (PLGA)
nanoparticles loaded with cyclosporine A showed a biphasic drug release profile and fit a
Weibull model of drug release.45
Three of the most common polymers for ocular drug delivery are: poly (alkyl
cyanoacrylates), polycaprolactone, and poly (lactic-co-glycolic acid).46 PLGA is a
biodegradable, nontoxic polymer that hydrolyzes into the nontoxic monomers lactic acid
and glycolic acid. PLGA nanoparticles have been used to deliver drugs to the retina.47 One
of the advantages of using PLGA as a drug delivery system is the tailorability of the drug
to the needs of the research team.48 The release time of drugs encapsulated in a PLGA shell
can be modified by varying the molecular weight of the polymer, the lactide:gylcolide ratio
of the polymer, and altering how the polymer /drug is combined.
Gupta, et. al. used PLGA to deliver sparfloxacin to improve precorneal penetration
time and increase the amount of drug in the vitreous humor.46 Gavini, et. al. utilized PLGA
microspheres to deliver vancomycin using spray drying manufacturing methods.49 The
13

research team found that the preparation of PLGA drug delivery vehicles was a suitable
method of drug delivery. Gupta, et. al. used PLGA nanoparticles loaded with the drug
sparfloxacin for ocular drug delivery for treatment of bacterial conjunctivitis.46 PLGA
nanoparticles have been shown to increase the ocular bioavability of drugs in the eye but
must be produced at a specific size range to prevent ocular irritation while still delivering
enough of the drug to treat the desired condition. Particle size and polydispersity were
found to influence the delivery of Sparfloxacin to the eye. PLGA nanoparticles under 250
nm were considered optimal for ocular drug delivery. Ocular irritation was tested through
the use of hen’s egg chorioallantoic membrane tests. Membrane tests were performed
because they are sensitive, inexpensive and the chorioallontic membrane is a whole tissue
that includes veins, arteries, and capillaries. Being a complete tissue, the chorioallontic
membrane responds with a total inflammatory response and is an appropriate method of
observing what biological reactions would occur in the eye.
Another study by Chang, et al. looked at the biocompatibility of PLGA
nanoparticles for ocular drug delivery.48 Albumin and doxycycline were fluorescently
labeled and loaded into PLGA using a water-oil-water double emulsion method.
Subconjunctival injections were used to evaluate the biocompatibility of PLGA particles
with the eye in murine animal models. The mice in the study received conjunctival
injections of 10 µL in both eyes and were euthanized after 14 days to observe the immune
response to the particles. Particles were found to be biocompatible and no significant ocular
inflammation was found. Drug release of the particles was also observed. The particles
exhibited an initial burst release followed by a slow sustained release out to 20 days,
indicating efficacy as a longer-term drug delivery product. Abrego, et al. looked at PLGA
14

particles loaded with pranoprofen for ocular drug delivery.50 The nanoparticles were
synthesized using a solvent displacement technique with polyvinyl alcohol as a stabilizer.
Ocular tolerance was tested using HET-CAM, and an irritation level of zero was obtained.
As can be seen from the above studies, PLGA is a drug delivery system that allows
customization based on the manufacturing parameters, the polymer itself and the drug
utilized. The tailorability of PLGA as well as the low levels of ocular irritation found
previously makes it an attractive drug delivery vehicle. There are several manufacturing
methods in which PLGA nanoparticles can be manufactured. In this project, PLGA
nanoparticles were synthesized using the spray drying manufacturing method which has
four primary manufacturing parameters that can be controlled: PLGA concentration
(w/v%), inlet temperature, flow rate, and lactide:gylcolide ratio of the PLGA.

G. Spray Drying Manufacturing Method
The spray drying manufacturing method of producing nanoparticles has a welldocumented history in scientific literature. It is a popular method to produce nanoparticles
in both research and in industry.52 Spray drying generates solid powders through the fast
drying of the carrier solvents.53,54 Understanding and controlling nanoparticle production
has gained more interest in the last decade.55 With the increase of research in nanoparticles
the spray drying manufacturing method has received more attention as a manufacturing
method of nanoparticles for drug delivery. Particles produced via spray drying are known
to have a primarily spherical morphology with few exceptions.
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Use of the Büchi Nano B-90 has been shown to produce particles that are spherical
with a high particle yield of up to 85% using a small amount of starting material.56 The
Büchi B-90 has a vibrating mesh and an electrostatic particle collector which allow better
control of the spray drying process.53,47 The mesh can reliably generate similarly sized
nanoparticles and the electrostatic particle collector ensures a better yield. There are several
parameters on the Büchi B-90 that can be controlled and changed when producing particles.
Two of the parameters for this experiment were optimized using the Büchi B-90 including
the air flow rate through the spray dryer and air inlet temperature, which indirectly controls
the temperature of the spray head. The other variables in the experiment were based on the
PLGA concentration and the amount of dasatinib used. Optimization of particle production
using a Büchi B-90 has been previously attempted by Sree Harsha, et. al. To create particles
of vitaglpitin, a new drug for diabetes, spray drying was optimized using three factors and
observing their effect on the formulation of the particles.57 However, optimization of the
spray drying process is sensitive to several factors, and thus must be repeated for each set
of drug/polymer/solvent combinations.
Lee et al. looked at the optimization of the spray drying of bovine serum albumin
(BSA) for particle size and axial morphology on a Büchi B-90 using a Taguchi design
approach.58 The levels that were used in this experiment were: spray mesh pore diameter,
BSA solution concentration, surfactant concentration, drying air flow rate, and inlet
temperature. The parameters that were found to have the most effect were spray mesh size
and surfactant concentration. Lee, et. al. proved that nanoparticles sprayed on a Büchi B90 can successfully be optimized to hit the desired target parameters using a logical
engineering approach through the use of a Taguchi design.
16

H. Instrumentation and Equipment

FIGURE 5. Büchi B-90 nano spray dryer59, 60
A Büchi B-90 nano spray dryer (Büchi, New Castle, DE.) was used to spray dry the
PLGA and PLGA dasatinib (PLGA-D) particles (figure 5). There are several functional
elements of the spray dryer that perform tasks necessary for particle formation.61At the
top of the spray dryer there is a heating element and the spray head itself. The heating
element heats the inlet air to the desired temperature and can produce temperatures up to
120˚ C. Droplet formation is achieved through the use of an ultrasonic nebulizer.
The ultrasonic nebulizer is in the spray head. It includes a piezoelectric actuator
with a thin stainless-steel membrane that contains micron-sized pores. Different sized
meshes having different average pore diameters allows the user to select a mesh to achieve
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the desired particle size. This stainless-steel membrane vibrates at ultrasonic frequencies
between 80-140 kHz which ejects droplets at the desired size. The droplets next encounter
the drying chamber, which uses conductive heat exchange between the drying gas and the
droplets.52 Particles form from the droplets as the solvent evaporate and are collected by
an electrostatic particle collector located at the base of the spray drying unit. The Büchi B90 Nano spray dryer also contains an outlet filter that collects the finest particles for
protection of the user and the environment. The drying gas is pumped into the drying
chamber via either an aspirator or compressed air, with the air flow rate controlled via an
inlet regulator.
For the spray drying of PLGA and PLGA-D, a flammable organic solvent,
dichloromethane, was utilized. This required the spray dryer to be operated with a Büchi
B-295 Inert Loop system that allows the spray dryer to be operated with the exclusion of
oxygen in the inlet gas. This prevents ignition of the solvent vapor, and also allows solvent
recycling and reduces cost.
As stated previously the Büchi B-90 can be optimized through careful experimental
design to determine which parameters contribute the most to particle size.62 Spray drying
on a Büchi B-90 presents a unique challenge because the machine has several different
components which can be optimized. Additionally, the PLGA and dasatinib concentrations
can also be studied to observe their effect on final particle size. Given the large number of
variables, a rational design is needed such as the Taguchi design like the one used by Lee,
et. al. to spray bovine serum albumin.
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I. Taguchi Matrix and Taguchi Design:
Design of experiments can be used to optimize a procedure, however, once several
variables become involved it becomes increasingly difficult and costly to perform. Taguchi
matrix design allows for the optimization of manufacturing parameters through the control
factors of the experiment. Taguchi design was developed by Dr. Genichi Taguchi and is a
technique which reduces the number of experiments through an orthogonal array and
minimization of out of control factors. Originally, it was used for improving the quality of
manufactured goods but has found application in other fields such as engineering and
biotechnology.64
Taguchi design reduces the number of experiments that need to be performed and
utilizes orthogonal arrays to achieve this. Orthogonal arrays are used to analyze many
design factors simultaneously.53 A loss function is used to measure the performance
characteristics that are deviating from the desired value.64 The value obtained from the loss
function is transformed into a signal-to-noise (S/N) ratio. The S/N value measures the
quality of the manufactured product with emphasis on product variation. Typically, the
designated trials from the Taguchi matrix are performed, and the set of parameters that
minimizes the S/N ratio for the desired outcome (in our case particle size) is selected.
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II.PROCEDURE
A. Chemical Supplies
PLGA with three different lactide:gylcolide ratios (65:35, 50:50, 75:25) was
purchased from Lactel Absorbal Polymers (Birmingham, AL). Dichloromethane and
phosphate buffered saline pH 7.4 (PBS) were supplied by Sigma-Aldrich (St. Louis, MO).
Dasatinib was supplied by Toronto Research Chemicals (Ontario, Canada).
B. Synthesis of PLGA and PLGA Dasatinib Solution:
PLGA particles of various lactide:glycolide ratios were dissolved in
dichloromethane at various weight by volume (% w/v) depending on the parameter
requirements in the Taguchi matrix (Table 1). This mixture was then sonicated for 10
minutes to ensure full dissolution of the PLGA into the DCM. The solution was kept on
ice while being spray-dried.
C. Spray Drying of PLGA Based on Taguchi Design:
PLGA and PLGA dasatinib solutions were spray dried using a Büchi B-90 Nano
spray dryer. Four parameters were manipulated to see what combination would yield the
smallest PLGA particle size. The parameters that were manipulated were: PLGA
concentration (w/v), lactide:glycolide linkage ratio of the PLGA, spray head inlet
temperature, and the flow rate of the spray dryer. These parameters were chosen based on
prior spray dries performed in the lab previously and by others. Schafroth, et al. also
utilized a Büchi 90 Nano spray dryer with PLGA dissolved in DCM and analyzed the effect
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of inlet temperature, flow rate, lactide:glycolide ratio on PLGA particles.65 They found that
the spray mesh diameter, sample flow rate, spray rate, and sample concentration had a
profound effect on the size of the PLGA particles produced providing another example that
spray drying parameters can be manipulated to optimize particle size.
TABLE I.
PARAMETERS FOR SPRAY DRYING PLGA PARTICLES
PARAMETER

DETAILS

LEVEL
1

2

3

A

PLGA concentration (w/v%)

1.5

2

2.5

B

Inlet temperature (°C)

40

45

50

C

Flow rate (L/min)

95

100

110

D

PLGA Ratio
(lactide:glycolide)

50:50

65:35

75:25

The parameters that were used were as follows: PLGA (w/v %) = 1.5%, 2.0%,
2.5%; Inlet temperature (ºC) = 40º, 45º, 50º; Flow rate (L/min) = 95, 100, 110; PLGA
(lactide: glycolide ratio) = 50:50, 65:35, 75:25. Level values for each parameter were
chosen based on Sree Harsha, et. al. and prior experiments in the O’Toole lab. A total of
nine different spray-drying runs were performed based on the combinations produced in
the Taguchi matrix. All nine PLGA sprays were done through a 4 µm spray mesh, as this
has consistently produced smaller particles in the lab than the other available mesh sizes.
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Table 1 shows the levels and parameters that were used for PLGA spray drying runs based
on the Taguchi matrix.
TABLE II.
TAGUHI MATRIX DESIGN RUNS AND LEVELS

Run 1
Run 2
Run 3
Run 4
Run 5
Run 6
Run 7
Run 8
Run 9

PLGA Concentration Inlet
Flow Rate
(w/v %)
Temperature (ºC) (L/min)
1
1
1
2
1
3
2
1
2
2
2
3
3
1
3
2
3
3

1
2
3
2
3
1
3
1
2

PLGA (Lactide:Glycolide
Ratio)
1
2
3
3
1
2
2
3
1

Dry particles were collected from the collecting drum using a nanoparticle scraper
manufactured by Büchi.
D. Spray Drying of PLGA Based on Best Taguchi Design
Following optimization, PLGA particles were spray-dried using the parameters in
the Taguchi matrix that yielded the smallest particle size, which was trial 1. Based on
analysis of the original Taguchi results three more spray drying trials of just PLGA were
completed using lower percent weight by volume (w/v %). The w/v % variations were:
0.25%, 0.5%, and 1% with all other parameters held the same as in trial
E. Spray Drying of PLGA Dasatinib Particles
PLGA dasatinib (PLGA-D) particles were produced using the same method as the
particles manufactured for the Taguchi optimization with the further synthesis step of the
addition of dasatinib. PLGA and dasatinib were dissolved in DCM using the parameters of
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the PLGA particles from Trial 1 which yielded the smallest particles. 0.025% dasatinib
w/v%, and 0.5% 50:50 PLGA were used in the synthesis of the new PLGA-D particles.
Dasatinib was then added to the PLGA/DCM mixture. The solution was then sonicated for
10 minutes to ensure full dissolution of the PLGA and dasatinib in the DCM.
PLGA dasatinib particles were spray dried using the following parameters:
40°C, 95 L/min flow rate, 0.5 (w/v%) 50:50 PLGA, and 0.025 (w/v%) dasatinib. These
parameters were chosen because they yielded the smallest PLGA particles. Different w/v
% of dasatinib were loaded into the particles to see how dasatinib loading affected particle
size and morphology.
F. Particle Characterization:

FIGURE 6. Zeiss Supra 35 SEM microscope65
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FIGURE 7. Plasma coater65
All particles were characterized using a Zeiss Supra 35 field emission scanning
electron microscope (Carl Zeiss Microscopy, LLC, Thornwood NY) shown in Figure 6.
Samples were prepared on SEM sample tacks and sputter coated for 30s with
gold/palladium using a plasma coater from International Scientific Instruments (New
Dehli, India seen in Figure 7. Images from the SEM were taken using EHT = 2 kV. ImageJ
software was utilized to analyze the particle diameter.67 For each Taguchi trial, a total of
ten different images were used with 100 particles being measured per image for a total of
n = 1000 particles. SEM images of the Taguchi trials can be seen in the appendix. Particle
diameter was based on the longest axial measurement of the particle. Statistical comparison
of particle size was performed using student t-tests with a p-value of 0.05.
The second optimization set of PLGA particles utilizing differing w/v% PLGA
were characterized using a minimum of 100 particles per image with at least five different
SEM images used per condition. PLGA-D particles were characterized with a minimum
of 1000 particles per condition.
In addition to the SEM images, particle stability in 1x PBS was analyzed using zeta
potential measurements on a ZetaPALS (Brookhaven). Higher absolute Zeta potential
values were interpreted to correlate with higher particle stability.

G. Statistical Analysis of Particle Size and Morphology:
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PLGA particle size optimization was performed through the use of a Taguchi
matrix. The parameters that were optimized can be seen in Table 1. Each parameter that
was optimized had three different levels which were chosen based on prior spray drying
done with PLGA in the O’Toole lab as well as other laboratories. Particle optimization
was based on minimizing particle diameter. Particle sizes were measured using ImageJ
software calibrated to the 10 µm scale bar on the SEM images. Signal-to-noise ratio (S/N)
was used to quantify particle optimization:
&5/

(𝑆/𝑁)& = −10𝑙𝑜𝑔/0 [2(𝑦&4 /𝑛)]
6

where n is the number of observations (in this case the number of particles measured
utilizing IMAGE J) and y is the output that is being measured (particle size). The S/N ratio
is used in the Taguchi design to identify the set of parameters that produce the desired
product with the least amount of noise.68 Noise is uncontrollable variability inherent to a
manufacturing procedure. The S/N ratio shows which parameters on the Taguchi matrix
produce particles with the lowest uncontrolled variation. This equation is used to minimize
the occurrence of undesirable particle characteristics such as particles that are too large. 69

H.Dasatinib Release Studies
A zero-time point release value was collected by rinsing 7 mg of PLGA dasatinib particles
in 1x phosphate buffer solution (PBS). The PBS was then removed using a pipet and
measurement of dasatinib content in the rinsed solution was measured using the UV-VIS
spectrum collected on a Cary 50 bio (Varian). Dasatinib concentration was evaluated at
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absorbance of 325 nanometers (nm). New 1x PBS was then added to the PLGA dasatinib
pellets and the dispersions were placed in a Thermo Scientific Series 8000 DH CO2
incubator at 37˚C and allowed to sit for 24 hours. After 24 hours had passed the 1x PBS
was removed utilizing a pipet and dasatinib quantified using the absorbance value at 325
nm. Measurement of PBS and subsequent replacement of fresh 1x PBS was performed for
a total of 30 days.
3.5
Absorbance (325 nm)

3

y = 0.0293x
R² = 0.9886

2.5
2
1.5
1
0.5
0
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80

90

100 110
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FIGURE 8. Dasatinib UV-Vis calibration curve
A calibration curve was prepared using dasatinib dissolved into 1x PBS the concentrations
of dasatinib used and the corresponding UV-VIS peaks obtained from the machine can be
seen in Figure 8
III. RESULTS AND DISCUSSION
A. Prior PLGA Dasatinib Particles
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PLGA and PLGA-D particles with sizes larger than one micrometer were produced in an
earlier study in the O’Toole lab. The release profiles of the particles were studied as was
their stability in 1x PBS, which presents a baseline for comparing the particles produced
utilizing the Taguchi matrix for optimization. Larger particles showed greater instability in
1x PBS as measured through zeta potential. Particles greater than 1 µm in size also showed
varied release profiles with release of dasatinib up to 40 days with seemingly random
release kinetic behavior. Larger particles also exhibited noticeable swelling and PLGA
aggregation at 15 days of suspension in the PBS.
B. PLGA and PLGA-D Optimization

Taguchi Matrix Particle Size Distribution
3.5
Particle Size (µm)

3
2.5
2
1.5
1
0.5
0
Series1

T1

T2

T3

T4

T5

T6

T7

T8

T9

1.21

1.87

1.64

1.88

2.46

1.60

1.68

1.53

1.54

FIGURE 9. PLGA particle size distribution
A total of nine trials were performed using the Taguchi matrix. All nine trials used a 4 µm
mesh with dichloromethane as the solvent.
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All trials were sprayed with the PLGA DCM solution kept on ice to keep the suspension
cold to reduce solvent evaporation and material degradation. Figure 9 shows a histogram
of the particle sizes that were obtained. Particle size and axial ratio was measured using
ImageJ software. Trial 1 produced the smallest particles with a size of 1.21 ± 0.6 µm.
PARTICLE SIZE (µM)

PARAMETERS
A

B

C

D

y (n=3)

1

1

1

1

1

1.20(0.61)

2

1

2

2

2

3

1

3

3

4

2

1

5

2

6

TRIAL

S/N ratio
(dB)

AXIAL RATIO
y
(n=3)

S/N RATIO
(DB)

-2.55

1.07

-1.74

1.87(0.60)

-5.87

1.03

-1.61

3

1.64(0.65)

-4.94

1.03

-1.08

2

3

1.88(0.71)

-6.06

1.09

-2.06

2

3

1

2.46(0.80)

-8.25

1.02

-1.24

2

3

1

2

1.60(0.55)

-4.51

1.00

0.01

7

3

1

3

2

1.68(0.69)

-5.16

1.07

-1.81

8

3

2

1

3

1.53(0.97)

-4.95

1.10

-1.52

9

3

3

2

1

1.54(0.91)

-5.02

1.02

-0.44

TABLE III
PLGA particle S/N ratio, size, and axial ration
The axial ratio of the particles is used to determine how circular the particles are by
measuring diameters across the apparent largest and smallest diameters of each particle. A
particle with an axial ratio measurement of 1 was considered spherical.70 5 images with
100 particles per image (500 total) were used to measure the axial ratio. As can be seen
from Table 3 all nine spray drying trials exhibited nearly spherical morphologies without
significant fluctuation in particle shape. Additionally, all particles had a smooth or slightly
rough surface appearance (see appendix).
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The impact of each of the four parameters used to spray dry the particles was then evaluated
by averaging the S/N ratio for all trials that shared a specific parameter level (e.g. A1).
After averaging each parameter level, the range for the given parameter was determined by
finding the difference between the highest and lowest S/N ratios within the parameter.
The effect on particle size can be seen

LEVEL

A

B

C

D

1

-4.46

-4.59

-4

-5.27

2

-6.27

-6.35

-5.65

-5.18

3

-5.04

-5.04

-6.12

-5.32

RANGE

1.81

1.76

2.12

0.05

RANK

2

3

1

4

in Table 4 and the effect on axial ratio
can be seen in Table 5. Particle size
was prioritized as the main target
outcome over particle circularity due
to heightened immune response in

TABLE IV.
Parameter level effect on particle size

swine eyes with larger particles found in
previous PLGA studies in the lab.

The parameters which had the largest effect on the particle size were the air flow rate of
the spray dryer and the w/v % of PLGA used to make the particles. However, regulation
LEVEL

A

B

C

D

1

-1.48

-1.87

-1.08

-1.14

2

-1.10

-1.46

-1.37

-1.14

B-90 in closed loop mode is erratic. The system relies

3

-1.26

-0.50

-1.38

-1.55

on input gas supplies from two different air cylinders

RANGE

0.38

1.37

0.30

0.41

(N2 and CO2) and the input is only triggered after a

RANK

3

1

4

2

TABLE V.
Parameter level effect on axial ratio

of the absolute air flow rate while operating the Büchi

minimum air pressure threshold is reached within the
spray dryer. As a result, system pressure and resulting
air flow could vary up to 50% during a single spray

drying run. Considering this, it was determined to focus on changing the PLGA
concentration, as this is a much more reliable and easily controlled parameter. The
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parameters with the greatest impact on the axial ratio of the particles were the inlet
temperature and lactide:glycolide ratio in the PLGA. The axial ratio measurements of the
particles in Table 6 show that all of the particles exhibited an axial ratio measurements
close to 1.
Use of the Taguchi approach allowed us to identify a set of parameters within our
matrix to produce the smallest particles, but more importantly, allowed us to identify which
parameters had the most effect on the outcome (particle size). Due to ease of adjusting
PLGA concentration, and the fact that intense immune responses were observed for larger
PLGA particles when injected into our porcine models (data not shown), we decided to
experiment with changing the particle size to levels outside of our original set of levels. As
Trial 1 produced the smallest particles out of all of the trials, the parameters that were used
for Trial 1 were 1.5% PLGA (w/v %), 40˚C inlet temperature, 95 L/min flow rate, and
50:50 PLGA lactide:gylcolide linkage ratio were chosen as starting points for further
experiments.
TABLE VI.
Varying PLGA w/v% effect on particle size and axial ratio
PLGA
CONCENTRATION
(WT/V%)
1.5
1.0
0.5

PARTICLE SIZE (µM)

AXIAL RATIO

y(n=3)
1.20(0.61)
0.83(0.37)
0.73(0.40)

y(n=3)
1.07
1.00
1.02

SNR (dB)
-2.55
0.51
1.62

SNR (dB)
-1.74
0.14
-0.48

The same S/N ratio used in our Taguchi approach was used to evaluate the impact of
varying w/v % PLGA on the particle size while adding trials with 0.5 and 1.0 w/v% PLGA.
SEM analysis of these extra trials showed that the lower the w/v% of the PLGA the smaller
the particle sizes that were produced, Table 6. 0.25% w/v% PLGA particles were also
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produced to see the effect of lowering the particle size. 0.25% w/v% PLGA particles did
not have a spherical morphology and as such were not desirable to go forward with for this
study images of these particles can be seen in the appendix. Particles produced with 0.5%
PLGA w/v were the smallest size at 0.73 ± 0.4 µm while still maintaining a circular axial
ratio of 1.02. These particles were considered most suitable for future in vivo studies, and
so these spray drying parameters were used for trials in which dasatinib was included for
encapsulation in the PLGA particles.

Figure 10. SEM of PLGA-D T1

Figure 12. SEM of PLGA-D T2

Figure 11. SEM of PLGA-D T3

TABLE VII.
Effect of levels on PLGA-D particle size and axial ratio
TRIALS

PARTICLE SIZE (µM)

AXIAL RATIO

1
2
3

y(n=3)
0.76(0.32)
0.73(0.35)
0.64(0.28)

y(n=3)
1.00
1.00
1.01

SNR (dB)
1.64
1.89
3.10
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SNR (dB)
-0.15
-0.48
-0.99

PLGA dasatinib (PLGA-D) particles were produced using the parameters for trial 1 with a
different w/v% PLGA of 0.5 because it had produced the smallest particles while
maintaining a spherical shape. The particles were spray dried with 0.025 w/v% dasatinib.
The concentration of dasatinib was chosen to maintain the minimum therapeutic level
found in prior studies such as the one by Umazume, et. al. over the desired release period.
Additionally, previous studies in the laboratory with PLGA-D showed that increasing from
0.025% (w/v) of dasatinib up to 0.25% (w/v) only increased the encapsulation efficiency
by 1.9-2.2 times. Supporting information from the previous PLGA-D encapsulation studies
can be seen in the appendix. From these experiments it was determined that using higher
concentrations of dasatinib for spray drying was not cost effective. Three sets of PLGA-D
particles were produced. Representative SEM images of each one of the three sets of
particles can be seen in Figures 10, 11, and 12.
SUB-MICROMETER PARTICLES(µM) ZETA POTENTIAL (MV) STDEV(MV)
0.76 ± 0.32
-17.32
4.81
0.73 ± 0.35
-20.69
3.27
0.64 ± 0.28
-29.93
2.11

Table VIII.
Zeta potential submicrometer particles
As can be seen from the SEM images all three sets of particles exhibited a
nearly spherical morphology which is corroborated by the axial ratio measurements in
Table 7 which are all close to 1. Two sets of the particles exhibited a perfectly spherical
morphology with an axial ratio score of 1.0. The last set of particles produced had an axial
ratio value of 1.01. The sizes of the particles that were produced were 0.76 ± 0.32 µm, 0.73
± 0.35 µm, and 0. 64 ± 0.28 µm. All three sets of particles hit a size below the
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target of 1 µm and exhibited the desired spherical morphology. Hela cells were found to
internalize more spherically shaped gold nanoparticles over rod shaped nanoparticles.19
Wooley, et. al. found that smaller spherical micelles had greater cellular uptake than larger
spherical micelles indicating that smaller more spherical nanoparticles increase cellular
uptake. Particle diameters were determined using ImageJ analysis of 8000 particles from
ten different SEM images.
The three sets of submicrometer particles exhibited enhanced stability as measured by the
zeta potential Table VIII when compared to previous micrometer sized particles. Table A2
in the appendix shows the zeta potential of PLGA and PLGA-D particles produced both in
this study and previously in the O’Toole lab. Submicrometer particles had a more negative
zeta potential which is considered to be less toxic to cells due to the cationic charge cells
have.71 Shao, et. al. found that
polymeric nanoparticles with a
more negative zeta potential
displayed

less

cytotoxicity

than polymeric nanoparticles
with a positive zeta potential.72
Nanoparticles (NP) with a
negative zeta potential were
Figure 13. Submicrometer particle controlled release

found to cause less damage to
cells due to their reduced

interaction with the cell membrane, and to undergo phagocytosis easier than their positively
charged counterparts. Negatively charged NPs were found to have weak interactions with
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lysosomes and the protein coronas that form around them due to the coronas also being
negatively charged.
Positively charged NPs were shown by Shao, et. al. to disrupt the formation of lysosomal
membranes and alter biological processes. A controlled release study was performed on all
three sets of PLGA-D particles and the results are shown in Figure 13.
The particles released detectable amounts of dasatinib out to 14 days. Unlike the larger
particles produced earlier in the study, the submicrometer particles all showed the same
drug release profile. The submicrometer particles had a rapid initial release of the drug with
60% of the dasatinib in the particles being released by the second day of the study. The
submicrometer particles released 94% of their dasatinib concentration within the first week
of the experiment and followed the Korsmeyer-Peppas model of drug release mechanisms
with Fickian Diffusion. The particle release matching to the Korsmeyer-Peppas model can

Cumulative % Drug
Released

be seen in the appendix.
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Figure 14. Submicrometer particle controlled release kinetics
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3.5

4

As can be seen from the graphs of the particle release kinetics all three sets of
submicrometer particles fit the same release profile whereas the larger particles produced
previously had different release profiles. Two additional sets of PLGA-D particles were
produced with the same parameters.
The two additional sets of particles that were produced were both under a micrometer in
size with sizes of: 0.97 ± 0.43 µm and 0.89 ± 0.57 µm, although their drug release kinetics
were not determined. The large standard deviations are due to fluctuations in internal
pressure of the spray dryer in the inert loop system which is a hallmark characteristic of
the spray drying manufacturing method.
IV. CONCLUSIONS AND RECOMMENDATIONS
Through use of a Taguchi statistical design, it has been shown that PLGA and PLGA
dasatinib particles smaller than one micrometer can be produced. These particles displayed
a spherical morphology with axial ratio measurements close to one. PLGA-D particle size
and morphology effects the immunological reaction by the body and the cellular uptake of
the particles. The smaller particle size and spherical morphology increases cellular uptake
and reduce immune response.
When loaded with dasatinib, all the submicrometer particles exhibited uniform release
kinetics and conformed to the Korsmeyer-Peppas release profile. The particles showed
rapid release of dasatinib with sustained dasatinib release up to 14 days. When compared
to larger PLGA and PLGA dasatinib particles produced previously in the lab, the smaller
particles exhibited greater stability as measured through zeta potential. More negative zeta
potential values have been found to be less cytotoxic.
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Further study could involve cellular contraction assays to observe the particles
effectiveness at preventing the contracture of retinal pigment epithelium. Additional work
that could be done is injecting optimized particles into animal models to observe how they
behave in vivo. A recommended animal study would be injecting the PLGA-D particles
into porcine models with induced PVR.
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Appendix:
Taguchi matrix PLGA SEM images

Figure A1. SEM image of Taguchi Trial 1

Figure A2. SEM image of Taguchi Trial 2
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Figure A3. SEM image of Taguchi Trial 3

Figure A4. SEM image of Taguchi Trial 4
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Figure A5. SEM image of Taguchi Trial 5

Figure A6. SEM image of Taguchi Trial 6
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Figure A7. SEM image of Taguchi Trial 7

Figure A8. SEM image of Taguchi Trial 8
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Figure A9. SEM image of Taguchi Trial 9

Figure A10. SEM image of 0.25% PLGA w/v% particles
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Submicrometer Particle Release Kinetics

LOG % CUMULATIVE DRUG RELEASE

KORSMEYER -PEPPAS MODEL (TRIAL1)
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2.000
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R² = 0.9675
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Figure A10. Trial 1 PLGA-D Particle Release Mechanisms

KORSMEYER PEPPAS (TRIAL 2)
LOG % CUMULATIVE DRUG RELEASE

Series1

-0.500

Linear (Series1)
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2.000
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y = 0.2395x + 1.4906
R² = 0.9974
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Figure A11. Trial 2 PLGA-D Particle Release Mechanisms
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1.500

2.000

Figure A12. Trial 3 PLGA-D Particle Release Mechanisms

Zeta Potential of PLGA and PLGA-D particles
PLGA-DASATINIB (µM)
0.76 ± 0.32
0.73 ± 0.35
0.64 ± 0.28
1.27 ± 0.58
1.11 ± 0.63
1.01 ± 0.33

Table A1. Zeta potential measurements of PLGA dasatinib particles

PLGA (µM)
0.83 ± 0.37
0.73 ± 0.40
0.62 ± 0.20
1.20 ± 0.61
1.63 ± 1.56
1.11 ± 0.28
Table A2. Zeta potential measurements of PLGA particles
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ZETA POTENTIAL (MV)
-17.32 ± 4.81
-20.69 ± 3.27
-29.93 ± 2.11
-3.95 ± 6.00
5.99 ± 12.74
-1.72 ± 2.60

ZETA POTENTIAL (MV)
-10.02 ± 1.38
-38.39 ± 3.55
-48.2 ± 1.43
24.42 ± 13.4
-16.95 ± 17.03
-2.3 ± 11.09
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